Drugplain

Fludeoxyglucose F18 300 mCi/mL

Fludeoxyglucose F-18 · INJECTION, SOLUTION · Biomedical Research Foundation of Northwest Louisiana

No Recall History
Plain English

Fludeoxyglucose F18 is a injection, solution containing fludeoxyglucose f-18 at 300 mCi/mL, taken intravenous. Manufactured by Biomedical Research Foundation of Northwest Louisiana.

Key Facts

Brand Name
Fludeoxyglucose F18
Generic Name
Fludeoxyglucose F-18
NDC Code (Product)
24562-003
Manufacturer
Biomedical Research Foundation of Northwest Louisiana
Strength
300 mCi/mL
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Marketing Status
Application #
ANDA203837
Drug Class
Radioactive Diagnostic Agent [EPC]
Marketing Start
05/14/2015

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

cytokine release syndrome23 reports
drug ineffective16 reports
nausea16 reports
off label use14 reports
neutropenia13 reports
platelet count decreased11 reports
pyrexia11 reports
bone marrow failure10 reports
death10 reports
hypotension10 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures (1) . 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular myocardium with

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Fludeoxyglucose F18 Injection emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description (11.2) ]. Fludeoxyglucose F18 Injection emits radiation. Use procedures to minimize radiation exposure. Screen for blood glucose abnormalities. In the oncology and neurology settings, instruct patients to fast for 4 – 6 hours prior to the drug’s injection. Consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to the drug’s administration (5.2) . In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to the drug’s injection facilitates localization of cardiac ischemia (2.3) . Aseptically withdraw Fludeoxyglucose F18 Injection from its container and administer by intravenous injection (2). The recommended dose: for adults is 5 – 10 mCi (185 – 370 MBq), in all indicated clinical settings (2.1) . for pediatric patients is 2.6 mCi in the neurology setting

Contraindications

4 CONTRAINDICATIONS None None

Drug Interactions

7 DRUG INTERACTIONS The possibility of interactions of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.

Adverse Reactions

6 ADVERSE REACTIONS Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available. Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available (6) . To report SUSPECTED ADVERSE REACTIONS, MIPS Cyclotron & Radiochemistry Facility at 650-725-4182 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Frequently Asked Questions

What is Fludeoxyglucose F18 used for?

Fludeoxyglucose F18 contains Fludeoxyglucose F-18. It is a injection, solution taken intravenous. Consult your doctor for specific uses.

Is Fludeoxyglucose F18 a controlled substance?

Fludeoxyglucose F18 is not classified as a controlled substance by the DEA.

What is the generic name for Fludeoxyglucose F18?

The generic name for Fludeoxyglucose F18 is Fludeoxyglucose F-18. There are 11 other brand versions of Fludeoxyglucose F-18.

What is the NDC code for Fludeoxyglucose F18 300 mCi/mL?

The NDC (National Drug Code) for Fludeoxyglucose F18 300 mCi/mL is 24562-003, listed by Biomedical Research Foundation of Northwest Louisiana.